🚀 Big news from #Hephaistos ⚙️ The #ETH startup
is launching its first industrial pilot with #SpiroChem, bringing de novo designed enzymes from the lab into real-world chemical synthesis > tinyurl.com/ynyja5nk
@ethz.ch #ETHstartup #Biotech #Biocatalysis #EnzymeDesign
is launching its first industrial pilot with #SpiroChem, bringing de novo designed enzymes from the lab into real-world chemical synthesis > tinyurl.com/ynyja5nk
@ethz.ch #ETHstartup #Biotech #Biocatalysis #EnzymeDesign
January 12, 2026 at 10:17 AM
🚀 Big news from #Hephaistos ⚙️ The #ETH startup
is launching its first industrial pilot with #SpiroChem, bringing de novo designed enzymes from the lab into real-world chemical synthesis > tinyurl.com/ynyja5nk
@ethz.ch #ETHstartup #Biotech #Biocatalysis #EnzymeDesign
is launching its first industrial pilot with #SpiroChem, bringing de novo designed enzymes from the lab into real-world chemical synthesis > tinyurl.com/ynyja5nk
@ethz.ch #ETHstartup #Biotech #Biocatalysis #EnzymeDesign
Interview with alumnus Marc Gitzinger, CEO of the D-BSSE spinoff Bioversys, specialised on combating #antimicrobial resistance and ‘hospital infections’ #ETHstartup @ethz.ch >
www.telezueri.ch/ceo-talk/ceo...
www.telezueri.ch/ceo-talk/ceo...
«CEO Talk» mit Marc Gitzinger, CEO Bioversys
Antibiotika-Resistenzen sind ein immer grösseres Problem. Sie erschweren die Behandlung vieler Infektionen, führen zu längeren oder auch schwereren Krankheitsverläufen. Laut Weltgesundheitsorganisatio...
www.telezueri.ch
May 12, 2025 at 7:44 AM
Interview with alumnus Marc Gitzinger, CEO of the D-BSSE spinoff Bioversys, specialised on combating #antimicrobial resistance and ‘hospital infections’ #ETHstartup @ethz.ch >
www.telezueri.ch/ceo-talk/ceo...
www.telezueri.ch/ceo-talk/ceo...